<DOC>
	<DOCNO>NCT01621165</DOCNO>
	<brief_summary>Mania consider , part , hyperadrenergic state . One focus treatment mania involve directly target hyperexcitable state reduce arousal antiadrenergic agent . This achieve decrease norepinephrine release stimulate presynaptic inhibitory receptor . Prazosin , FDA approve treatment high blood pressure work part block postsynaptic alpha-adrenergic receptor . Prazosin find clinically useful treatment Post Traumatic Stress Disorder . It reasonable , therefore , anticipate prazosin might helpful treatment mania .</brief_summary>
	<brief_title>Prazosin Antimanic Agent Severe Mania Mixed States</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<mesh_term>Antimanic Agents</mesh_term>
	<criteria>Age 1860 Primary diagnosis bipolar disorder severe mania mixed episode YMRS score &gt; 20 Documented medical evaluation without acute serious medical illness Negative pregnancy test Healthy functioning liver Lack capacity provide inform consent Involuntary commitment Low blood pressure History adverse reaction allergy prazosin quinazolines Informed consent give retract study History narcolepsy Unstable acute medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>treatment bipolar , mania</keyword>
	<keyword>double-blind , placebo-controlled study</keyword>
	<keyword>drug intervention</keyword>
	<keyword>add-on study</keyword>
	<keyword>prazosin</keyword>
	<keyword>alpha-1 adrenergic antagonist</keyword>
</DOC>